ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Alexza Pharmaceuticals has received $50 million from private equity firm Symphony Capital Partners to support the development of two drugs for the psychiatric market. AZ-002, for panic attacks, and AZ-004, for agitation in schizophrenia patients, are both in Phase IIa clinical trials. Alexza says the cash will facilitate its goal of bringing the drugs to market on its own. Alexza has granted the private equity firm a license to the intellectual property related to the two drugs, but Alexza retains the option to buy it back at a set price during the next four years.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter